scholarly journals Study effect of IL-35 and some sex hormones in male patients who have multiple sclerosis (MS)

2015 ◽  
Vol 3 (1) ◽  
pp. 38
Author(s):  
Ali K. Bidan ◽  
Nisreen A. Hamzah
Keyword(s):  
Multiple Sclerosis ◽  
Early Treatment ◽  
Treatment Initiation ◽  
Accurate Diagnosis ◽  
Control Group ◽  
Relapsing Remitting ◽  
Male Patients ◽  
Group 2 ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Group 1

<p>Multiple sclerosis (MS) is a disease characterized by inflammation and demyelination. Currently, the cause of MS is unknown. An early and accurate diagnosis of multiple sclerosis (MS) is very important, since it allows early treatment initiation, which reduces the activity of the disease. The present study aimed to focus a light on the contribution of interlukin-35 (IL-35) and its relation to some hormones such as testosterone, progesterone, and prolactin (PRL) in the pathogenesis of multiple sclerosis. Twenty two enrollers (samples) attended from Teaching hospital of Baghdad were divided into two groups. Ten enrollers were described as healthy subject as control group as group 1 (G1) in range ages (20-30) years. Twelve male patients as group 2 (2) have been relapsing remitting multiple sclerosis (RRMS) matched in age with group 1 (G1).</p>

scholarly journals Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases

2008 ◽  
Vol 66 (1) ◽  
pp. 11-14 ◽  
Author(s):  
Sergio Semeraro Jordy ◽  
Charles Peter Tilbery ◽  
Mirella Martins Fazzito
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Center ◽  
Immunomodulatory Treatment ◽  
Relapsing Remitting ◽  
Group 3 ◽  
The Mean ◽  
Remitting Multiple Sclerosis ◽  
Group 2 ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Group 1

BACKGROUND: Since 1997, immunological modulators have been used for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the Multiple Sclerosis Attendance and Treatment Center (CATEM) with significant alterations in this disease natural history. AIM: To add data on the experience of CATEM for the treatment of RRMS patients that had immunomodulators. METHOD: RRMS patients that received continuously immunomodulator drugs were evaluated on adherence, migration, withdrawal and progression rates. The patients were divided in three groups by the period of immunomodulators intake. RESULTS: There were registered in Group 1 withdrawal in 98 patients (25%) and adherence in 292 cases (74%); Group 2 interruption of therapy in 140 patients, 92 (31%) due to progression for PSMS, 14 (5%) for pregnancy, withdrawal in 34 (11%), adherence in 88%; Group 3 progression in 41 (26%), pregnancy in 3 (2%) withdrawal in 42 (27%) and adherence in 72%. The migration rate was about one third (31.57%) and the principal cause was therapeutic failure; the mean migrating time was 0.5-2.5 years in group 3. CONCLUSION: Immunomodulatory treatment for RRMS patients may have significant levels of failure and side effects; the adherence was compatible with the international literature.

scholarly journals Relationship between Expanded Disability Status Scale scores and the presence of temporomandibular disorders in patients with multiple sclerosis

2018 ◽  
Vol 12 (01) ◽  
pp. 144-148 ◽  
Author(s):  
Lucas Senra Correa Carvalho ◽  
Osvaldo José Moreira Nascimento ◽  
Luciane Lacerda Franco Rocha Rodrigues ◽  
Andre Palma Da Cunha Matta
Keyword(s):  
Multiple Sclerosis ◽  
Temporomandibular Disorders ◽  
Control Group ◽  
Expanded Disability Status Scale ◽  
Exact Test ◽  
Disability Status ◽  
Relapsing Remitting ◽  
Scale Scores ◽  
Axis I ◽  
Relapsing Remitting Multiple Sclerosis

ABSTRACTObjectives: The objectives of this study were to assess the prevalence of temporomandibular disorders (TMDs) in patients with relapsing-remitting multiple sclerosis (MS) and to investigate whether an association exists between the presence of TMD symptoms and the degree of MS-related disability. Materials and Methods: In all, 120 individuals were evaluated: 60 patients with a diagnosis of relapsing-remitting MS and 60 age- and sex-matched controls without neurological impairments. A questionnaire recommended by the European Academy of Craniomandibular Disorders for the assessment of TMD symptoms was administered. For those who answered affirmatively to at least one of the questions, the RDC/TMD Axis I instrument was used for a possible classification of TMD subtypes. The Expanded Disability Status Scale (EDSS) was the measure of the degree of MS-related disability. Statistical Analysis Used: Fisher’s exact test was used to analyze the data. ANOVA was used to detect significant differences between means and to assess whether the factors influenced any of the dependent variables by comparing means from the different groups. Results: The prevalence of TMD symptoms in patients with MS was 61.7% versus 18.3% in the control group (CG). A diagnosis of TMD was established for 36.7% in the MS group and 3.3% in the CG (P = 0.0001). There were statistically significant differences between degrees of MS-related disability and the prevalence of TMD (P = 0.0288). Conclusions: The prevalence of both TMD and TMD symptoms was significantly greater in the MS group. EDSS scores and TMD prevalence rates were inversely related.

New versus old: Implications of evolving diagnostic criteria for relapsing–remitting multiple sclerosis

2018 ◽  
Vol 25 (6) ◽  
pp. 867-870 ◽  
Author(s):  
Nuala McNicholas ◽  
Andrew Lockhart ◽  
Siew M Yap ◽  
Karen O’Connell ◽  
Niall Tubridy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Cerebrospinal Fluid ◽  
Accurate Diagnosis ◽  
Oligoclonal Bands ◽  
Mcdonald Criteria ◽  
International Panel ◽  
Relapsing Remitting ◽  
Time To Diagnosis ◽  
Relapsing Remitting Multiple Sclerosis

The International Panel on Diagnosis of Multiple Sclerosis (MS) recently revised the 2010 McDonald criteria and made recommendations for revision, allowing for the earliest possible, accurate diagnosis of MS. For relapsing–remitting MS, positive, unmatched cerebrospinal fluid oligoclonal bands may substitute for dissemination in time. Symptomatic lesions, including brainstem and spinal cord, may demonstrate dissemination in space or in time if enhancing (with the exception of the optic nerve). Cortical and juxtacortical lesions are equivalent. In this retrospective analysis, we applied revised criteria to 250 patients previously diagnosed with relapsing–remitting MS according to 2010 criteria and assessed for change in diagnostic times. There was a significant improvement in time to diagnosis between 2010 and 2017 groups ( p < 0.01). Median time to diagnosis according to McDonald 2010 was 7.4 months, compared with 2.3 months for McDonald 2017. Use of cerebrospinal fluid results most frequently resulted in a reduction in time to diagnosis. Symptomatic gadolinium-enhancing lesions led to earliest diagnostic times.

Comparison of conservative management and juvenile pubic symphysiodesis in the early treatment of canine hip dysplasia

2008 ◽  
Vol 21 (03) ◽  
pp. 267-279 ◽  
Author(s):  
G. Dravelli ◽  
L. Vezzoni ◽  
M. De Lorenzi ◽  
A. Corbari ◽  
A. Cirla ◽  
...  
Keyword(s):  
Early Treatment ◽  
Hip Dysplasia ◽  
Skeletal Maturity ◽  
Negative Control Group ◽  
Negative Control ◽  
Control Group ◽  
Homogeneous Groups ◽  
Group 2 ◽  
Canine Hip Dysplasia ◽  
Group 1

Summary Objectives: To evaluate the efficacy of juvenile pubic symphysiodesis (JPS) in a clinical setting for the early treatment of canine hip dysplasia (CHD), and to identify its indications and contraindications. Methods: The final degree of CHD using the FCI (Fédération Cynologique Internationale) CHD classification in 5 Grades (A, B, C, D, E) was assessed at skeletal maturity in two homogeneous groups of dogs assessed at the age of 14 to 22 weeks and selected according to their susceptibility to CHD; one group was treated with JPS and one group was conservatively managed. Two hundred seventeen puppies completed the study; 81 were treated with JPS (group 1) and 76 were conservatively managed (group 2). A third group of 60 puppies with normal hips was followed as a negative control group. Results: In group 1, 43.2% of the puppies had regression or a lack of progression of the disease in the final evaluation (Grade A & B), 25.9% had mild CHD (Grade C) and 30.9% had moderate and severe CHD (Grade D & E). In group 2, 23.6% of the puppies did not show any development of the disease (Grade A & B), 21.1% had mild CHD (Grade C) and 55.3% developed moderate to severe CHD (Grade D & E). Further investigation was done by comparing the severity of early signs of susceptibility to CHD with the final FCI Grades at adulthood in both groups. Clinical significance: The JPS procedure increased the odds of arresting or limiting the progression of CHD in mild to moderate grades of CHD, while it was less effective or ineffective in more severe forms.

Axonal Degeneration Independent of Inflammatory Activity: Is It More Intense in the Early Stages of Relapsing-Remitting Multiple Sclerosis Disease?

2020 ◽  
Vol 83 (5) ◽  
pp. 508-516
Author(s):  
Vedat Cilingir ◽  
Muhammed Batur
Keyword(s):  
Multiple Sclerosis ◽  
Axonal Degeneration ◽  
Early Stage ◽  
Early Years ◽  
Inflammatory Activity ◽  
Control Group ◽  
Relapsing Remitting ◽  
Duration Of Disease ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

<b><i>Background:</i></b> This study aimed to investigate whether there are differences in the axonal degeneration rate between patients in the early years of relapsing-remitting multiple sclerosis (RRMS) disease and RRMS patients in their later years. <b><i>Methods:</i></b> The early-stage RRMS patients (EMS) group had 65 patients whose duration of disease was within 3 years from the date of the first attack. The late-stage RRMS patients (LMS) group had 69 patients whose duration of disease was within the range of 3–10 years from the date of the first attack. In addition, a control group was composed of 32 healthy subjects. Peripapillary retinal nerve fiber layer (RNFL) thickness was monitored with spectral-domain OCT in all included patients for approximately 3 years. <b><i>Results:</i></b> The annual RNFL atrophy rate (aRNFLr) in the EMS group was −1.246 ± 0.778 μm/year, the aRNFLr in the LMS group was −0.898 ± 0.536 μm/year, and the aRNFLr was −0.234 ± 0.154 μm/year in the control group (<i>p</i> &#x3c; 0.001). The aRNFLr in the EMS group was significantly higher than the aRNFLr in the LMS group (<i>p</i> = 0.01). The aRNFLr was not associated with MRI activity or the condition of having an attack. There was a correlation between Expanded Disability Status Scale (EDSS) progression and aRNFLr in both the EMS and LMS patient groups (<i>r</i> = −0.471, <i>p</i> &#x3c; 0.001, and <i>r</i> = −0.567, <i>p</i> &#x3c; 0.001, respectively). <b><i>Conclusion:</i></b> The axonal degeneration rate is faster in RRMS patients in the first years of the disease than in later years. In addition, axonal degeneration occurs independently of inflammatory activity. Axonal degeneration is correlated with disability progression, but not with inflammatory findings, such as clinical episodes and MRI activity.

Sign in / Sign up

Export Citation Format

Share Document